By Andy Smith, Director of Life Sciences at AlphaSense
For pharmaceutical companies, competitive advantage has always depended on the ability to identify change early, including shifts in clinical activity, emerging market demands, competitor movement, and regulatory developments. But the sheer volume and complexity of healthcare data make that task increasingly difficult to manage through traditional methods alone.
AI is changing that dynamic. Rather than relying on staff to manually monitor fragmented sources of information, pharmaceutical firms are turning to AI-powered intelligence for research that can analyse vast datasets in real time and surface actionable insights at speed.
Staying ahead of competitor activity and pipeline shifts is a critical, ongoing workflow for life sciences teams — particularly competitive intelligence, R&D, clinical strategy, business development, and commercial teams. Without it, teams risk being surprised by clinical readouts, regulatory milestones, deal activity, or emerging competitors that can quickly alter the market landscape.
Using traditional manual search, teams must sift through earnings transcripts, conference presentations, trial registries, press releases, regulatory filings, and industry news — often spread across dozens of disparate sources — increasing the risk of missed signals, surfacing inaccurate information, and delays in forming insights.
AI can enable pharma and life sciences organizations to analyse vast volumes of information with the intent of identifying market movements, go-to-market risks, and new revenue opportunities far faster and with greater breadth than teams of workers or stitched together tools can perform. However, even with the possibilities of automating search and market intelligence with AI, trust is still the major differentiator. These organizations must be able to trust and verify the outputs from AI to inform their decision making, which means the AI should be sourcing from only vetted, premium business content. With AI-enabled search based in high-trust content, leading pharmaceutical companies stay continuously informed and strategically proactive.
In this way, what was once a retrospective monitoring exercise is now a forward-looking strategic capability, one that helps organisations monitor competitor pipelines, track clinical milestones, and analyze strategic positioning to ultimately make faster, more confident decisions.
As adoption continues to accelerate, the companies seeing greatest value are those going beyond automated search to embed AI across the full intelligence workflow.
But what does this mean in practice?
AI’s practical role in reshaping the drug development process
Perhaps the most meaningful competitive advantage for pharma companies using AI is the potential for a drastic reduction in research and development timelines. Pharmaceutical firms are getting ahead by adopting platforms with domain-specific data and content that provide a single, integrated view of the competitive landscape for greater efficiency and more accurate results versus juggling many different research tools.
For many, the ability to delve into clinical trial updates, government regulatory activity, disease landscaping, and partnership, merger, and acquisition deals in one unified space provides a decision-ready view of the market. However, integrating AI into the business is only the first step. Firms can gain the most advantage from deploying agentic workflows purpose-built for their unique complex life sciences and pharmaceutical workstreams. These workflows use agents that understand roles, tasks, and deliverables to execute against for specific workstreams with minimal human oversight. This enables AI to provide users with exactly what they need, when they need it, tailored to their exact specifications, based on verified content, retaining trust and nearly eliminating the risk of hallucinations.
While AI research is redefining keeping pace with innovation, AI is also creating a material impact on the speed in which drugs are being developed.
An example is seen with preclinical acceleration; according to the UK’s “AI for science strategy“, one of the missions is to “accelerate drug discovery to develop trial-ready drugs within 100 days by 2030 and contribute to deploying new treatments faster.” AI also offers more efficient screening practices, with AI tools able to narrow down a library of 100 compounds to the most promising leads in one to two days, a process that typically takes a month using manual, brute force methods.
But what about the speed-accuracy trade off? For drug development, the early signals are positive, with AI-designed drugs showing an 80-90% success rate in safety trials, nearly double the historical average of 40% to 65%.
The significant reduction in timeline and increase in success rate is pivotal for drug development. Even marginal improvements in proficiency through AI can allow a company to surge ahead of its competitors, with firms using AI in research and development gaining the potential to understand a market need, analyse relevant factors and market signals, and bring a drug to market faster than a competitor.
Breaking down the divide between commercial and clinical teams
Speed isn’t the only benefit. AI is enabling commercial strategy and clinical decision-making to reposition as a unified, data-driven ecosystem where business operations and patient care are no longer operating separately.
Acting as the connecting point, AI is empowering pharmaceutical companies to re-evaluate and engage differently with the broader network. Using real-time alerts for specific companies, assets, regulatory decisions, or development milestones, teams can share these insights to drive market strategy. This functionality is vital in a fast-changing market where a single clinical data release, regulatory decision, or licensing announcement can reshape decisions overnight.
Beyond timely alerts, however, lies the ability for pharma companies to understand the why, which is the rich contextual information contained within specialized documentation such as broker research, expert interviews with key thought leaders embedded in industries, and trending information on specific business sectors, or “channels”. When using this deeply layered approach, companies can gain a penetrative market view that extends beyond what is available on publicly available sources of information and understand a true pulse of a company, market, sector, or investment environment.
The shift among pharma and biotech companies can be viewed as adapting from generic “one-size-fits-all” models to highly targeted, AI-enabled execution. Companies of every size in the industry are scaling AI across commercial operations toward better business outcomes like dynamically targeting their audiences, personalising messaging, and making more targeted investment decisions. For example, Pfizer is scaling AI across 1,200 GPUs specifically for dynamic targeting, research, and development. In addition, commercial teams are using AI to identify exact patient cohorts that are most likely to benefit from a therapy or drug treatment.
When it comes to actual clinical outcomes, AI is already transforming decision-making. Intelligent Decision Support Systems (IDSS) analyse vast datasets to flag potential drug interactions, prioritise high impact alerts, and reduce alert fatigue for clinicians. AI-powered imaging analysis also is proving reliable in diagnosing and detecting health concerns, with accurate results being reported within cancer detection.
The next competitive frontier in pharma
As AI becomes more deeply embedded into more workflows, the targeted outcomes are moving beyond productivity gains toward how effectively companies can use AI to improve quality, speed and consistency of strategic decision-making in the industry.
What increasingly separates leading organisations from the rest is seeing how extensively they have integrated AI into core operational and commercial processes. For some, AI remains a supplementary tool used to automate individual tasks. For others, it is becoming foundational to how decisions are made, influencing everything from research priorities and go-to-market planning.
At the same time, successful adoption will depend on maintaining trust in the outputs AI generates. Human expertise, scientific understanding, and strong governance all remain essential in validating insights and ensuring responsible use. Organisations that combine a human-centric approach with AI-led insight and domain expertise will achieve a true competitive edge.